Literature DB >> 25380977

A review on the efficacy and safety of gabapentin in the treatment of chronic cough.

Nicole M Ryan1.   

Abstract

INTRODUCTION: Effective antitussives available to control cough are limited. Consolidation among different afferent branches of the vagus nerve is needed to bring about cough. A general, widely accepted view is that the chronic increase in the sensitivity of the cough reflex is associated with inflammatory hypersensitivity such as from gastro-esophageal reflux disease. There is increasing evidence that an important mechanism is a sensory disorder of the laryngeal branches of the vagus nerve. Neuromodulating drugs are effectively used in the treatment of chronic pain and neuropathic disorders and may have a role in the treatment of refractory chronic cough (CC). AREAS COVERED: Current evidence on the efficacy and safety of gabapentin in the treatment of CC is reviewed. Relevant randomized controlled trials, case reports and reviews were identified through a PubMed search of English-language literature referring to cough, sensory neuropathy and gabapentin over the last 10 years. EXPERT OPINION: Gabapentin appears to be effective and well tolerated in the treatment of CC and in other sensory neuropathic disorders. Relevant clinical trials investigating its efficacy and safety profile in the treatment of cough are limited and further studies are needed. Gabapentin has been shown to cause minimal to no toxicity in overdose.

Entities:  

Keywords:  central sensitization; chronic cough; gabapentin; sensory laryngeal neuropathy; toxicity

Mesh:

Substances:

Year:  2014        PMID: 25380977     DOI: 10.1517/14656566.2015.981524

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  8 in total

Review 1.  Symptom management in the older adult: 2015 update.

Authors:  Thomas J Smith
Journal:  Clin Geriatr Med       Date:  2015-03-03       Impact factor: 3.076

2.  Symptomatic Treatment of Cough Among Adult Patients With Lung Cancer: CHEST Guideline and Expert Panel Report.

Authors:  Alex Molassiotis; Jaclyn A Smith; Peter Mazzone; Fiona Blackhall; Richard S Irwin
Journal:  Chest       Date:  2017-01-17       Impact factor: 9.410

Review 3.  An update and systematic review on drug therapies for the treatment of refractory chronic cough.

Authors:  Nicole M Ryan; Anne E Vertigan; Surinder S Birring
Journal:  Expert Opin Pharmacother       Date:  2018-04-16       Impact factor: 3.889

4.  Effect of pregabalin for the treatment of chronic refractory cough: A case report.

Authors:  Jun Li; Ling Ye
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

5.  Prediction of therapeutic efficacy of gabapentin by Hull Airway Reflux Questionnaire in chronic refractory cough.

Authors:  Mengru Zhang; Qiang Chen; Ran Dong; Li Yu; Zisheng Ai; Xianghuai Xu; Zhongmin Qiu
Journal:  Ther Adv Chronic Dis       Date:  2020-12-26       Impact factor: 5.091

Review 6.  Danish respiratory society position paper: palliative care in patients with chronic progressive non-malignant lung diseases.

Authors:  Kristoffer Marsaa; Svend Gundestrup; Jens-Ulrik Jensen; Peter Lange; Anders Løkke; Nassim Bazeghi Roberts; Saher Burhan Shaker; Anita Rath Sørensen; Ingrid Louise Titlestad; Laura Hohwü Thomsen; Ulla Møller Weinreich; Elisabeth Bendstrup; Torgny Wilcke
Journal:  Eur Clin Respir J       Date:  2018-10-16

Review 7.  Management of chronic refractory cough in adults.

Authors:  Dina Visca; Bianca Beghè; Leonardo Michele Fabbri; Alberto Papi; Antonio Spanevello
Journal:  Eur J Intern Med       Date:  2020-09-19       Impact factor: 4.487

Review 8.  Mechanisms and Rationale for Targeted Therapies in Refractory and Unexplained Chronic Cough.

Authors:  Stuart B Mazzone; Lorcan McGarvey
Journal:  Clin Pharmacol Ther       Date:  2020-08-28       Impact factor: 6.875

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.